SCHEMBL1652259

SCHEMBL1652259

Nc1sc(N)c2cnccc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 1/20 0.45
EP300 Q09472 1/20 0.45
KAT2B Q92831 1/20 0.45
KAT8 Q9H7Z6 1/20 0.45
CYP2D6 P10635 3/20 0.42
LMNA P02545 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 2/20 0.42
CYP1A2 P05177 1/20 0.42
CLK1 P49759 2/20 0.41
DYRK1A Q13627 1/20 0.41
IMPDH2 P12268 3/20 0.39
KDM4E B2RXH2 3/20 0.38
HTT P42858 2/20 0.38
POLB P06746 1/20 0.38
RAD52 P43351 1/20 0.38
GAA P10253 2/20 0.38
CDK5 Q00535 1/20 0.38
CDK5R1 Q15078 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16755955 0.72 AXL (0.50) AXLEP300KAT2BKAT8CYP2D6
SCHEMBL19587052 0.71 GAA (0.53) AXLEP300KAT2BKAT8CYP2D6
SCHEMBL5894746 0.70 AXL (0.72) AXLEP300KAT2BKAT8CYP2D6
Hydrochloric Acid SCHEMBL28051932 0.70 GAA (0.51) AXLEP300KAT2BKAT8CYP2D6
SCHEMBL11885002 0.67 KDM4E (0.44) AXLEP300KAT2BKAT8CYP2D6
SCHEMBL11884982 0.67 CYP2A6 (0.42) AXLEP300KAT2BKAT8DYRK1A
SCHEMBL5864604 0.67 CLK1 (0.38) AXLEP300KAT2BKAT8CYP2D6
SCHEMBL11150652 0.67 IMPDH2 (0.39) AXLEP300KAT2BKAT8CYP2D6
SCHEMBL16433152 0.67 EP300 (0.45) AXLEP300KAT2BKAT8CYP2D6
SCHEMBL1094972 0.67 AXL (0.36) AXLEP300KAT2BKAT8CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3238708-A1 INHALANT FORMULATION CONTAINING CYCLODEXTRIN AND CORTICOSTEROID CyDex Pharmaceuticals, Inc. (US) 2017-11-01 EP disclosed
EP-2173169-B1 NASAL DELIVERY OF AQUEOUS CORTICOSTEROID SOLUTIONS CYDEX PHARMACEUTICALS INC (US) 2014-05-21 EP disclosed
US-7927613-B2 Pharmaceutical co-crystal compositions UNIVERSITY OF SOUTH FLORIDA (US) 2011-04-19 US disclosed
US-7790905-B2 Pharmaceutical propylene glycol solvate compositions MCNEIL-PPC, INC. (US) 2010-09-07 US disclosed
EP-2173169-A1 NASAL AND OPHTHALMIC DELIVERY OF AQUEOUS CORTICOSTEROID SOLUTIONS CyDex Pharmaceuticals, Inc. (US) 2010-04-14 EP disclosed
EP-2043599-A1 INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID CyDex Pharmaceuticals, Inc. (US) 2009-04-08 EP disclosed
WO-2009003199-A1 NASAL AND OPHTHALMIC DELIVERY OF AQUEOUS CORTICOSTEROID SOLUTIONS CYDEX PHARMACEUTICALS, INC. (US) 2008-12-31 WO disclosed
EP-1732512-A4 INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID CYDEX INC (US) 2008-07-23 EP disclosed
WO-2008005802-A2 NASAL FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID CYDEX PHARMACEUTICALS, INC. (US) 2008-01-10 WO disclosed
WO-2008005053-A1 INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID CYDEX PHARMACEUTICALS, INC. (US) 2008-01-10 WO disclosed
EP-1732512-A2 INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID Cydex Inc. (US) 2006-12-20 EP disclosed
WO-2005065435-A2 INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID CYDEX, INC. ET AL. (US) 2005-07-21 WO disclosed